Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
June 29, 2021
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
Abstract: The present invention relates to a use of a pharmaceutical composition which includes a carbamate compound of chemical formula 1 and is administered to prevent, alleviate, or treat tremors or tremor syndrome.
Abstract: The present invention relates to an orally disintegrated tablet and a method for producing same, the tablet containing a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, as an active ingredient.
Type:
Application
Filed:
December 14, 2017
Publication date:
March 25, 2021
Applicant:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Myoung Ki BAEK, So Young CHOI, Ji Hye LEE
Abstract: The present invention relates to a use for preventing, alleviating or treating pruritus by administering a pharmaceutical composition comprising a carbamate compound of following Formula 1.
Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fibromyalgia or a functional syndrome associated with fibromyalgia, the pharmaceutical composition comprising: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, a solvate or a hydrate; and a pharmaceutically acceptable carrier. The pharmaceutical composition, according to the present invention, may enable the efficient treatment of fibromyalgia or a functional syndrome associated with fibromyalgia.
Abstract: The present invention relates to a newly identified solvate form of (i?)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.
Type:
Grant
Filed:
September 6, 2017
Date of Patent:
November 10, 2020
Assignees:
Jazz Pharmaceuticals Ireland Limited, SK Biopharmaceuticals Co., Ltd.
Abstract: The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity: wherein R1 and R2 are the same as defined herein.
Abstract: The present invention relates to a use for preventing, alleviating or treating pruritus by administering a pharmaceutical composition comprising a carbamate compound of following Formula 1.
Abstract: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.
Type:
Grant
Filed:
May 18, 2018
Date of Patent:
December 17, 2019
Assignee:
SK Biopharmaceuticals Co., Ltd.
Inventors:
Moise A. Khayrallah, Gary Bream, Stephen E. Butts, Susan Marie Melnick, Duncan Taylor
Abstract: The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.
Type:
Application
Filed:
March 21, 2019
Publication date:
December 5, 2019
Applicants:
SK BIOPHARMACEUTICALS CO., LTD., SK BIOPHARMACEUTICALS CO., LTD.
Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
Abstract: The present invention relates to a pharmaceutical composition for preventatively treating headaches, containing: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt, solvent or hydrate thereof; and a pharmaceutically acceptable carrier. According to the present invention, the pharmaceutical composition can effectively prevent a headache, more specifically, headaches caused by cortical spreading depression, and particularly, chronic headaches including migraines.
Abstract: A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
October 29, 2019
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Cheol Young Maeng, Young Koo Jang, Su Bong Cha, Hye Won Shin, Chan Mi Joung, Eun Jung Yi
Abstract: The present invention relates to a use for the purpose of preventing, alleviating, or treating bipolar disorder by administering a pharmaceutical composition comprising a carbamate compound of the following chemical formula 1.
Abstract: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic
Type:
Grant
Filed:
February 15, 2017
Date of Patent:
July 16, 2019
Assignee:
SK Biopharmaceuticals Co., Ltd.
Inventors:
Abdallah Ahnaou, Wilhelmus H. I. M. Drinkenburg, Joseph Palumbo, Jonathan Sporn
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating trigeminal neuralgia, the pharmaceutical composition comprising: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, a solvate or a hydrate; and a pharmaceutically acceptable carrier. The pharmaceutical composition, according to the present invention, may enable the efficient prevention or treatment of trigeminal neuralgia.
Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
Abstract: The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
Type:
Grant
Filed:
January 30, 2017
Date of Patent:
April 16, 2019
Assignees:
Jazz Pharmaceuticals International III Limited, SK Biopharmaceuticals Co., Ltd.
Inventors:
Moise A. Khayrallah, Gary Bream, Stephen E. Butts
Abstract: The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.